142 related articles for article (PubMed ID: 12858188)
21. Long-term retinal transgene expression with FIV versus adenoviral vectors.
Loewen N; Leske DA; Cameron JD; Chen Y; Whitwam T; Simari RD; Teo WL; Fautsch MP; Poeschla EM; Holmes JM
Mol Vis; 2004 Apr; 10():272-80. PubMed ID: 15094709
[TBL] [Abstract][Full Text] [Related]
22. Restricted transgene persistence after lentiviral vector-mediated fetal gene transfer in the pregnant rabbit model.
Moreno R; Rosal M; Martinez I; Vilardell F; Gonzalez JR; Petriz J; Hernandez-Andrade E; Gratacós E; Aran JM
J Gene Med; 2008 Sep; 10(9):951-64. PubMed ID: 18613266
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
24. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
25. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
[TBL] [Abstract][Full Text] [Related]
26. Lentivirus vectors: difficulties and hopes before clinical trials.
Kafri T
Curr Opin Mol Ther; 2001 Aug; 3(4):316-26. PubMed ID: 11525555
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
28. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
29. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice.
Bouchard S; MacKenzie TC; Radu AP; Hayashi S; Peranteau WH; Chirmule N; Flake AW
J Gene Med; 2003 Nov; 5(11):941-50. PubMed ID: 14601131
[TBL] [Abstract][Full Text] [Related]
30. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy.
Pellinen R; Hakkarainen T; Wahlfors T; Tulimäki K; Ketola A; Tenhunen A; Salonen T; Wahlfors J
Int J Oncol; 2004 Dec; 25(6):1753-62. PubMed ID: 15547714
[TBL] [Abstract][Full Text] [Related]
31. Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus.
Waddington SN; Buckley SM; Bernloehr C; Bossow S; Ungerechts G; Cook T; Gregory L; Rahim A; Themis M; Neubert WJ; Coutelle C; Lauer UM; Bitzer M
Gene Ther; 2004 Apr; 11(7):599-608. PubMed ID: 14724676
[TBL] [Abstract][Full Text] [Related]
32. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
33. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.
Cao B; Bruder J; Kovesdi I; Huard J
Gene Ther; 2004 Sep; 11(17):1321-30. PubMed ID: 15175641
[TBL] [Abstract][Full Text] [Related]
34. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
35. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.
Liehl B; Hlavaty J; Moldzio R; Tonar Z; Unger H; Salmons B; Günzburg WH; Renner M
Gene Ther; 2007 Sep; 14(18):1330-43. PubMed ID: 17611586
[TBL] [Abstract][Full Text] [Related]
36. Newborn liver gene transfer by an HIV-2-based lentiviral vector.
Salani B; Damonte P; Zingone A; Barbieri O; Chou JY; D'Costa J; Arya SK; Eva A; Varesio L
Gene Ther; 2005 May; 12(10):803-14. PubMed ID: 15772691
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector.
McCormack JE; Edwards W; Sensintaffer J; Lillegren L; Kozloski M; Brumm D; Karavodin L; Jolly DJ; Greengard J
Mol Ther; 2001 Apr; 3(4):516-25. PubMed ID: 11319912
[TBL] [Abstract][Full Text] [Related]
38. Gene transfer to the gastrointestinal tract after peroral administration of recombinant adeno-associated virus type 2 vectors.
Shao G; Greathouse K; Huang Q; Wang CM; Sferra TJ
J Pediatr Gastroenterol Nutr; 2006 Aug; 43(2):168-79. PubMed ID: 16877980
[TBL] [Abstract][Full Text] [Related]
39. Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro.
Teng Q; Garrity-Moses M; Federici T; Tanase D; Liu JK; Mazarakis ND; Azzouz M; Walmsley LE; Carlton E; Boulis NM
Neurobiol Dis; 2005 Dec; 20(3):694-700. PubMed ID: 16005636
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
